Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / Venrock Adviser, LLC
Form 13F · Q2 2026

Venrock Adviser, LLC

CIK 1615982Filed 2026-08-1413F-HR View the filing on EDGAR ↗
$3.3B
Reported book value
33
Positions
12
Quarters on record
Top 50
Positions

Venrock Adviser, LLC — holdings

Top 33 positions of 33, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1APOGEE THERAPEUTICS INC Apogee Therapeutics Inc8.5M+0.0%$1.1B34.2%
2ORKA Oruka Therapeutics Inc4.1M+0.0%$395M12.0%
3ERAS Erasca Inc17.9M+9.2%$328M9.9%
4SYRE Spyre Therapeutics Inc3.0M−19.0%$265M8.0%
5DNTH Dianthus Therapeutics Inc1.2M+0.0%$115M3.5%
6OCUL Ocular Therapeutix Inc10.3M+0.0%$102M3.1%
7DMRA Damora Therapeutics Inc3.6M+0.0%$94M2.8%
8SVRA Savara Inc14.7M+7.3%$91M2.8%
9JBIO Jade Biosciences Inc3.2M+0.0%$72M2.2%
10COGT Cogent Biosciences Inc1.6M−17.9%$64M1.9%
11VRDN Viridian Therapeutics Inc3.3M−16.1%$60M1.8%
12VOR Vor Biopharma Inc3.0M+0.0%$56M1.7%
13DYN Dyne Therapeutics Inc2.2M+0.0%$48M1.5%
14MAZE Maze Therapeutics Inc1.6M+0.0%$48M1.4%
15RLMD Relmada Therapeutics Inc6.8M+41.3%$47M1.4%
16ORIC Oric Pharmaceuticals Inc4.3M+0.0%$47M1.4%
17CBIO Crescent Biopharma Inc.2.1M+0.0%$38M1.2%
18ZURA Zura Bio Ltd6.4M+0.0%$38M1.2%
19ANL Adlai Nortye Ltd3.2M+0.0%$37M1.1%
20ELVN Enliven Therapeutics Inc526,331−69.5%$27M0.8%
21CYBIN INC Cybin Inc3.9M+0.0%$25M0.8%
22CGEM Cullinan Therapeutics Inc1.4M+0.0%$25M0.8%
23IPSC Century Therapeutics Inc8.7M+0.0%$21M0.6%
24ARTV Artiva Biotherapeutics Inc2.0M+27.0%$20M0.6%
25CTMX Cytomx Therapeutics Inc.5.0M−50.1%$19M0.6%
26QUIT Achieve Life Science Inc2.8M—$18M0.5%
27PBLS Parabilis Medicines Inc625,000—$17M0.5%
28SRZN Surrozen Inc632,931+0.0%$16M0.5%
29KRRO Korro Bio Inc1.0M+0.0%$13M0.4%
30ANRO Alto Neuroscience Inc500,000+0.0%$13M0.4%
31XFOR X4 Pharmaceuticals Inc1.9M+485.2%$9M0.3%
32RACC Research Alliance Corp Iii300,000—$3M0.1%
33MTRI Inmed Pharmaceuticals Inc32,685—$50,6620.0%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.